Prudential Financial
CTKB icon

Prudential Financial’s Cytek Biosciences CTKB Stock Holding History

Prudential Financial’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
23,260
-94,337
-80% -$403K ﹤0.01% 2337
2026
Q1 		$514K Buy
117,597
+10,740
+10% +$50.7K ﹤0.01% 1856
2025
Q4 		$540K Sell
106,857
-5,810
-5% -$27K ﹤0.01% 1809
2025
Q3 		$391K Hold
112,667
– – ﹤0.01% 2024
2025
Q2 		$383K Buy
112,667
+6,285
+6% +$20.9K ﹤0.01% 2032
2025
Q1 		$427K Sell
106,382
-67,000
-39% -$347K ﹤0.01% 1891
2024
Q4 		$1.13M Buy
173,382
+63,600
+58% +$379K ﹤0.01% 1530
2024
Q3 		$608K Buy
109,782
+6,700
+6% +$38K ﹤0.01% 2132
2024
Q2 		$575K Sell
103,082
-9,150
-8% -$55K ﹤0.01% 2108
2024
Q1 		$753K Sell
112,232
-1,345
-1% -$10.6K ﹤0.01% 1974
2023
Q4 		$1.04M Sell
113,577
-2,610
-2% -$16.4K ﹤0.01% 1801
2023
Q3 		$641K Buy
116,187
+16,000
+16% +$128K ﹤0.01% 1964
2023
Q2 		$856K Buy
+100,187
New +$899K ﹤0.01% 1884

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prudential Financial's CTKB Position: Q2 2026 in Review

Prudential Financial reduced its Cytek Biosciences (CTKB) stake by 80% in Q2 2026, selling an estimated $403K and leaving 23,260 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Prudential Financial first reported a position in CTKB in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.13M in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Prudential Financial held 23,260 shares of Cytek Biosciences worth $103K as of Q2 2026.
  • Prudential Financial sold 94,337 Cytek Biosciences shares in Q2 2026, an estimated $403K.
  • Cytek Biosciences made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2337 holding.
  • Prudential Financial first reported a position in Cytek Biosciences in Q2 2023 and has held it in 13 quarters since.
  • Prudential Financial's Cytek Biosciences position peaked at $1.13M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.